Terconazole

Summary

Terconazole (CHEMBL1714574) is an approved small molecule (ATC G01AG02); indicated across 2 conditions including vulvovaginal candidiasis and vaginitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AG02
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 532.5 Da · C26H31Cl2N5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1714574
Name	Terconazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5404
ChEBI	CHEBI:82979
ATC	G01AG02
Molecular formula	C26H31Cl2N5O3
Molecular weight	532.5
InChIKey	BLSQLHNBWJLIBQ-UHFFFAOYSA-N

SMILES: CC(C)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl

IUPAC name: 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine

ChEBI definition: A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by 2,4-dichlorophenyl, 1H-1,2,4-triazol-1-ylmethyl, and [4-(4-isopropylpiperazin-1-yl)phenoxy]methyl groups, respectively.

Also known as: Fungistat, Gyno-terazol, NSC-331942, Panlomyc, R 42470, R-42,470, R-42470, Terazol 3, Terazol 7, Terconazol, Terconazole, Tercospor

Patent coverage: 8 distinct patent families (21 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14 (67%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 39 (assay-derived). Sample: Prelamin-A/C, Muscarinic acetylcholine receptor M4, Tyrosine-protein kinase Fyn, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Thyrotropin receptor, Beta-lactamase, Muscarinic acetylcholine receptor M5, D(1A) dopamine receptor.

Bioactivity

ChEMBL activities: 47 potent at pChembl ≥ 5 of 72 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.1	Potency	7.9	nM	CHEMBL_ACT_3624974
ADRA2C	7.21	Ki	61	nM	CHEMBL_ACT_7812633
HRH3	7.02	AC50	96	nM	CHEMBL_ACT_25199945
SIGMAR1	6.67	Ki	214	nM	CHEMBL_ACT_7816844
ADRA2A	6.43	Ki	369	nM	CHEMBL_ACT_7812629
P06762	6.39	IC50	410	nM	CHEMBL_ACT_19258619
ADRA2C	6.38	IC50	418	nM	CHEMBL_ACT_7812632
SIGMAR1	6.29	IC50	508	nM	CHEMBL_ACT_7816843
ADRA2A	6.01	IC50	983	nM	CHEMBL_ACT_7812628
ADRA2B	5.9	Ki	1246	nM	CHEMBL_ACT_7812631
CHRM1	5.86	Ki	1375	nM	CHEMBL_ACT_7814760
HSP90AA1	5.85	AC50	1415	nM	CHEMBL_ACT_7453852
CYP3A4	5.8	Potency	1585	nM	CHEMBL_ACT_4985523
CYP3A4	5.8	Potency	1585	nM	CHEMBL_ACT_5050757
CYP3A4	5.8	AC50	1585	nM	CHEMBL_ACT_6053751
DRD3	5.8	Ki	1600	nM	CHEMBL_ACT_7814702
CHRM4	5.72	Ki	1913	nM	CHEMBL_ACT_7814766
ADRA2A	5.7	AC50	1996	nM	CHEMBL_ACT_25156842
HSP90AA1	5.66	AC50	2190	nM	CHEMBL_ACT_7457658
HTR2A	5.63	Ki	2336	nM	CHEMBL_ACT_7816830
P12530	5.61	IC50	2446	nM	CHEMBL_ACT_7814749
O70528	5.61	Ki	2463	nM	CHEMBL_ACT_7816838
ADRA2B	5.56	IC50	2729	nM	CHEMBL_ACT_7812630
CYP51A1	5.52	IC50	3000	nM	CHEMBL_ACT_2122885
CHRM3	5.51	Ki	3081	nM	CHEMBL_ACT_7814764
CHRM5	5.5	Ki	3134	nM	CHEMBL_ACT_7814768
HTR2C	5.44	Ki	3646	nM	CHEMBL_ACT_7816834
SLC6A3	5.36	Ki	4347	nM	CHEMBL_ACT_7814706
CHRM5	5.36	IC50	4362	nM	CHEMBL_ACT_7814767
CHRM2	5.34	Ki	4590	nM	CHEMBL_ACT_7814762

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
vulvovaginal candidiasis	3	MONDO:0006014	EFO:0007543
vaginitis	0	MONDO:0002234	MONDO:0002234

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02308007	PHASE3	COMPLETED	Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308046	PHASE3	COMPLETED	Multi-Center Study of New Medications to Treat Vaginal Infections
NCT03473418	PHASE3	UNKNOWN	Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).